Journal
EMERGING MICROBES & INFECTIONS
Volume 7, Issue -, Pages -Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1038/s41426-018-0102-5
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [31470892, 91442102]
- National Key Research and Development Project [2016YFC1200900]
- National Science and Technology Major Project of the Ministry of Science and Technology of China [2015ZX09102025002]
- Guangzhou Health Care and Cooperative Innovation Major Project [201508020252, 201803040004]
- CAS Youth Innovation Promotion Association [2014328]
Ask authors/readers for more resources
Ebolavirus vaccines based on several adenoviral vectors have been investigated in preclinical studies and clinical trials. The use of adenovirus serotype 2 as a vector for ebolavirus vaccine has not been reported. Herein, we generated rAd2 ZGP, a recombinant replication-incompetent adenovirus serotype 2 expressing codon-optimized Zaire ebolavirus glycoprotein, and evaluated its immunogenicity in mice and rhesus macaques. rAd2-ZGP induced significant antibody and cell-mediated immune responses at 2 weeks after a single immunization. The glycoprotein (GP)-specific immune responses could be further enhanced with a booster immunization. Compared to protein antigens, Zaire ebolavirus GP and Zaire ebolavirus-like particles, rAd2-ZGP could induce stronger cross-reactive antibody and cell-mediated immune responses to heterologous Sudan ebolavirus in mice and rhesus macaques. In rAd2-ZGP-immunized macaques, GP-specific CD8(+) T cells could secret IFN-gamma and IL-2, indicating a Th1-biased response. In adenovirus serotype 5 seropositive macaques, rAd2-ZGP could induce robust antibody and cell-mediated immune responses, suggesting that the efficacy of rAd2-ZGP is not affected by pre-existing immunity to adenovirus serotype 5. These results demonstrated that rAd2-ZGP can be considered an alternative ebolavirus vaccine for use in adenovirus serotype 5 seropositive subjects or as a sequential booster vaccine after the subjects have been immunized with a recombinant adenovirus serotype 5-based vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available